Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이동현 | - |
dc.date.accessioned | 2016-12-13T02:12:27Z | - |
dc.date.available | 2016-12-13T02:12:27Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.other | OAK-4917 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/233108 | - |
dc.description.abstract | Purpose: To develop a reliable prognostic model for patients with metastatic renal cell carcinoma (RCC) based on features readily available in common clinical settings. Patients and Methods: A total of 197 patients with RCC who underwent nephrectomy and immunotherapy from 1995 to 2004 were retrospectively reviewed. Their mean age was 55.1 ± 11.8 yrs (24-83 yrs) and mean survival time from metastasis was 22.6 ± 20.2 mos (3-120 mos). The impact of 24 clinicopathological features on disease specific survival was investigated. Results: On univariate analysis, constitutional symptoms, sarcomatoid differentiation, tumor necrosis, multiple primary lesions, liver metastasis, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), thrombocytosis, alkaline pbosphatase, hematocrit, T stage, N stage, and nuclear grade had significant influence on survival (p < 0.05). Multivariate analysis revealed the following features associated with survival: sarcomatoid differentiation [hazard ratio (HR)=2.99, p<0.001], liver metastasis (HR = 2.09, p = 0.002), ECOG-PS (HR = 1.95, p = 0.005), N stage (HR = 1.94, p = 0.002), and number of metastatic sites (HR = 1.76, p = 0.003). An individual prognostic score was defined as the sum of the weight of these features. According to prognostic scores, patients could be subdivided into 3 groups: low risk (score 0), intermediate risk (score 1 or 2), and high risk (score ≥ 3). Conclusion: A comprehensive prognostic stratification model was developed to predict survival and stratify patients for prospective clinical trials. | - |
dc.language | English | - |
dc.title | A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma | - |
dc.type | Article | - |
dc.relation.issue | 3 | - |
dc.relation.volume | 49 | - |
dc.relation.index | SCI | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.index | KCI | - |
dc.relation.startpage | 451 | - |
dc.relation.lastpage | 458 | - |
dc.relation.journaltitle | Yonsei Medical Journal | - |
dc.identifier.doi | 10.3349/ymj.2008.49.3.451 | - |
dc.identifier.wosid | WOS:000257277000016 | - |
dc.identifier.scopusid | 2-s2.0-48649083951 | - |
dc.author.google | Cho K.S. | - |
dc.author.google | Choi Y.D. | - |
dc.author.google | Kim S.J. | - |
dc.author.google | Kim C.I. | - |
dc.author.google | Chung B.H. | - |
dc.author.google | Seong D.H. | - |
dc.author.google | Lee D.H. | - |
dc.author.google | Cho J.S. | - |
dc.author.google | Cho I.R. | - |
dc.author.google | Hong S.J. | - |
dc.contributor.scopusid | 이동현(24341048900;57202299352) | - |
dc.date.modifydate | 20230331134421 | - |